BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression.

J Immunother Cancer · 2022 · PMC9472153 · PMID 36096532

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a statistical trendno p-value reported

A statistical trend was observed for the group treated with BND-22 +anti-PD-1 in comparison to the isotype control group (one-way ANOVA followed by Dunnett’s multiple comparisons; p=0.0586).

also in 2,798 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.